Phenomic AI starts with $6M using AI/ML for Targeting the Tumor Stroma
Phenomic AI, a Canadian biotechnology company that uses an AI/ML platform for targeting the tumor stroma, has launched with $6
Read morePhenomic AI, a Canadian biotechnology company that uses an AI/ML platform for targeting the tumor stroma, has launched with $6
Read moreRoche revealed on Monday that Venclexta ® (venetoclax) in conjunction with azacitidine or decitabine or low-dose cytarabine (LDAC) has been
Read moreEli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreViiV Healthcare’s GEMINI studies showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine, appeared to have non-inferior potency in
Read moreBristol Myers Squibb is strengthening its cardiovascular pipeline through a $13.1 Billion acquisition of biotech firm MyoKardia. The $13.1 Billion
Read moreAstraZeneca’s FARXIGA® was granted Breakthrough Therapy Designation (BTD) in the U.S. for Chronic Kidney Disease, following the DAPA-CKD Phase III
Read moreAbbott declared the first patient has been enrolled in the DISTINCT study (Dorsal spInal cord STImulatioN vs mediCal management for
Read moreJanssen’s Golimumab, a human monoclonal antibody used as an immunosuppressive drug and sold under the brand name Simponi, has received
Read moreSwiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read morePhase 3 clinical trials for the COVID-19 vaccine named AZD1222, developed by AstraZeneca and Oxford University, have been paused after
Read more